Ying Wang1, Megan Delisle2, Denise Smith3, Bader Alshamsan4,5, Amirrtha Srikanthan6,7,8. 1. Division of Medical Oncology, Department of Medicine, University of British Columbia, Vancouver, BC, V5Z 4E6, Canada. 2. Division of Surgery, The Ottawa Hospital, Ottawa, ON, K1H8L6, Canada. 3. McMaster University, Health Sciences Library, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada. 4. Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada. 5. Department of Medicine, College of Medicine, Qassim University, Buraydah, Saudi Arabia. 6. Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada. asrikanthan@toh.ca. 7. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. asrikanthan@toh.ca. 8. Ottawa Hospital Research Institute, Ottawa, ON, K1Y4E9, Canada. asrikanthan@toh.ca.
Abstract
BACKGROUND: Brain metastasis in sarcomas is associated with a poor prognosis. Data regarding prognostic factors and clinical outcomes of surgical resection of brain metastasis from sarcomas are limited. The objective of this systematic review was to evaluate survival outcomes post-brain metastasectomy for patients with soft tissue and bone sarcomas. METHODS: A systematic review was conducted examining survival outcomes among adults and children with soft tissue and bone sarcoma undergoing brain metastasectomy, in the English language from inception up to May 31, 2021. Two reviewers independently evaluated and screened the literature, extracted the data, and graded the included studies. The body of evidence was evaluated and graded according to the Newcastle-Ottawa Quality Assessment Scale for Cohort Studies and the Joanna Briggs Institute Critical Appraisal Checklist for Case Series. Results were synthesized using descriptive methods. A meta-analysis was not possible due to the low quality and heterogeneity of studies. RESULTS: Ten studies published between 1994 and 2020 were included: three were retrospective cohort studies and seven were case series. 507 patients were included, of whom 269 underwent brain metastasectomy. The median follow-up period ranged between 14 and 29 months. The median survival period after metastasectomy ranged from 7 to 25 months. The most common prognostic factors associated with survival included presenting performance status, age, number of brain metastases, presence of lung metastases, and peri-operative radiation therapy administration. DISCUSSION: Although the level of evidence is low, retrospective studies support that brain metastasectomy can be performed with reasonable post-operative survival in selected individuals.
BACKGROUND: Brain metastasis in sarcomas is associated with a poor prognosis. Data regarding prognostic factors and clinical outcomes of surgical resection of brain metastasis from sarcomas are limited. The objective of this systematic review was to evaluate survival outcomes post-brain metastasectomy for patients with soft tissue and bone sarcomas. METHODS: A systematic review was conducted examining survival outcomes among adults and children with soft tissue and bone sarcoma undergoing brain metastasectomy, in the English language from inception up to May 31, 2021. Two reviewers independently evaluated and screened the literature, extracted the data, and graded the included studies. The body of evidence was evaluated and graded according to the Newcastle-Ottawa Quality Assessment Scale for Cohort Studies and the Joanna Briggs Institute Critical Appraisal Checklist for Case Series. Results were synthesized using descriptive methods. A meta-analysis was not possible due to the low quality and heterogeneity of studies. RESULTS: Ten studies published between 1994 and 2020 were included: three were retrospective cohort studies and seven were case series. 507 patients were included, of whom 269 underwent brain metastasectomy. The median follow-up period ranged between 14 and 29 months. The median survival period after metastasectomy ranged from 7 to 25 months. The most common prognostic factors associated with survival included presenting performance status, age, number of brain metastases, presence of lung metastases, and peri-operative radiation therapy administration. DISCUSSION: Although the level of evidence is low, retrospective studies support that brain metastasectomy can be performed with reasonable post-operative survival in selected individuals.
Authors: Eduardo N Novais; Bahtiyar Demiralp; Joseph Alderete; Melissa C Larson; Peter S Rose; Franklin H Sim Journal: Clin Orthop Relat Res Date: 2010-11 Impact factor: 4.176
Authors: Stanley P L Leong; Blake Cady; David M Jablons; Julio Garcia-Aguilar; Douglas Reintgen; J Jakub; S Pendas; L Duhaime; R Cassell; M Gardner; R Giuliano; V Archie; D Calvin; L Mensha; S Shivers; C Cox; J A Werner; Y Kitagawa; M Kitajima Journal: Cancer Metastasis Rev Date: 2006-06 Impact factor: 9.264
Authors: Ghadah Al Sannaa; Kelsey L Watson; Adriana Olar; Wei-Lien Wang; Gregory N Fuller; Ian McCutcheon; Keila E Torres; Alexander J Lazar Journal: Ann Surg Oncol Date: 2016-09-19 Impact factor: 5.344
Authors: William G Kraybill; Jonathon Harris; Ira J Spiro; David S Ettinger; Thomas F DeLaney; Ronald H Blum; David R Lucas; David C Harmon; G Douglas Letson; Burton Eisenberg Journal: J Clin Oncol Date: 2006-02-01 Impact factor: 44.544